Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06414434 · ClinicalTrials.gov registry record · Phase 1
BTX-A51 in Patients With Liposarcoma or CIC-rearranged Sarcoma
A Phase 1 study of Liposarcoma and Recurrent Liposarcoma, sponsored by Michael Wagner, MD.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
- 2
- Study locations
NCT06414434 is a Phase 1 study of Liposarcoma and Recurrent Liposarcoma that is actively recruiting participants, run by Michael Wagner, MD. The registered enrollment target is 24 participants, below the 83-participant average among 13 other Liposarcoma trials with a reported enrollment target (71% lower). The trial reports 2 study locations across 1 state.
The verdict
NCT06414434, a Phase 1 study of Liposarcoma and Recurrent Liposarcoma, is actively recruiting participants, sponsored by Michael Wagner, MD.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
- 2
- Study locations
Study Summary
This study is testing two different doses of BTX-A51 to determine if it is safe and tolerable in participants with liposarcoma with MDM2 amplification, myxoid liposarcoma, and CIC-rearranged sarcoma. The name of the study drug used in this research study is: -BTX-A51 (a type of kinase inhibitor)
Conditions Studied
Interventions
- DRUG BTX-A51
Study Locations (2)
Massachusetts
- Brigham and Women's Hospital - Boston
- Dana-Farber Cancer Institute - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2024-09-30 |
| Est. Completion | 2027-06-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06414434
The ClinicalTrials.gov registry entry for NCT06414434 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 83-participant average among 13 other Liposarcoma trials with a reported enrollment target (71% lower). The listed sponsor is Michael Wagner, MD, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 7 conditions, with Liposarcoma appearing as the primary indexed condition, and to 1 intervention - of which BTX-A51 is the first listed.
NCT06414434 reports 2 study locations spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06414434 about?
NCT06414434 is a clinical study titled "BTX-A51 in Patients With Liposarcoma or CIC-rearranged Sarcoma". This study is testing two different doses of BTX-A51 to determine if it is safe and tolerable in participants with liposarcoma with MDM2 amplification, myxoid liposarcoma, and CIC-rearranged sarcoma. The name of the study drug used in this research study is: -BTX-A51 (a type of kinase inhibitor)
What is the current status of trial NCT06414434?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2024-09-30. Estimated completion is 2027-06-01.
What conditions does trial NCT06414434 study?
This clinical trial studies the following conditions: Liposarcoma, Recurrent Liposarcoma, Unresectable Liposarcoma, Myxoid Liposarcoma, Metastatic Liposarcoma.
What interventions are being tested in trial NCT06414434?
The interventions under investigation include: BTX-A51 (DRUG).
Who is sponsoring clinical trial NCT06414434?
This trial is sponsored by Michael Wagner, MD, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06414434 being conducted?
This trial has 2 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Liposarcoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors
RECRUITING · Phase 1
-
Immunotherapy For Adults With GPC3-Positive Solid Tumors Using IL-15 and IL-21 Armored GPC3-CAR T Cells
RECRUITING · Phase 1
-
Immunotherapy for Solid Tumor Malignancies in Pediatrics Using Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor T Cells
RECRUITING · Phase 1
-
A Study of Mirdametinib in Combination With Palbociclib in People With Liposarcoma
RECRUITING · Phase 1
-
Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors
RECRUITING · Phase 1
-
NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.